Matija Snuderl

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7540822/publications.pdf Version: 2024-02-01



MATHA SNUDEDI

#	Article	IF	CITATIONS
1	DNA methylation-based classification of central nervous system tumours. Nature, 2018, 555, 469-474.	27.8	1,872
2	Classification and mutation prediction from non–small cell lung cancer histopathology images using deep learning. Nature Medicine, 2018, 24, 1559-1567.	30.7	1,768
3	New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs. Cell, 2016, 164, 1060-1072.	28.9	702
4	Near real-time intraoperative brain tumor diagnosis using stimulated Raman histology and deep neural networks. Nature Medicine, 2020, 26, 52-58.	30.7	413
5	Rapid intraoperative histology of unprocessed surgical specimens via fibre-laser-based stimulated Raman scattering microscopy. Nature Biomedical Engineering, 2017, 1, .	22.5	374
6	B-cell Lymphomas With Concurrent IGH-BCL2 and MYC Rearrangements Are Aggressive Neoplasms With Clinical and Pathologic Features Distinct From Burkitt Lymphoma and Diffuse Large B-cell Lymphoma. American Journal of Surgical Pathology, 2010, 34, 327-340.	3.7	327
7	Aspartate is a limiting metabolite for cancer cell proliferation under hypoxia and in tumours. Nature Cell Biology, 2018, 20, 775-781.	10.3	311
8	Modeling Patient-Derived Glioblastoma with Cerebral Organoids. Cell Reports, 2019, 26, 3203-3211.e5.	6.4	293
9	T2–FLAIR Mismatch, an Imaging Biomarker for IDH and 1p/19q Status in Lower-grade Gliomas: A TCGA/TCIA Project. Clinical Cancer Research, 2017, 23, 6078-6085.	7.0	285
10	Detection of human brain tumor infiltration with quantitative stimulated Raman scattering microscopy. Science Translational Medicine, 2015, 7, 309ra163.	12.4	249
11	Sarcoma classification by DNA methylation profiling. Nature Communications, 2021, 12, 498.	12.8	237
12	Targeting Placental Growth Factor/Neuropilin 1 Pathway Inhibits Growth and Spread of Medulloblastoma. Cell, 2013, 152, 1065-1076.	28.9	209
13	Increase in tumor-associated macrophages after antiangiogenic therapy is associated with poor survival among patients with recurrent glioblastoma. Neuro-Oncology, 2013, 15, 1079-1087.	1.2	205
14	Merlin/NF2 Loss-Driven Tumorigenesis Linked to CRL4DCAF1-Mediated Inhibition of the Hippo Pathway Kinases Lats1 and 2 in the Nucleus. Cancer Cell, 2014, 26, 48-60.	16.8	198
15	Glioblastoma Recurrence after Cediranib Therapy in Patients: Lack of "Rebound―Revascularization as Mode of Escape. Cancer Research, 2011, 71, 19-28.	0.9	186
16	Hacking macrophage-associated immunosuppression for regulating glioblastoma angiogenesis. Biomaterials, 2018, 161, 164-178.	11.4	184
17	Polymorphous low-grade neuroepithelial tumor of the young (PLNTY): an epileptogenic neoplasm with oligodendroglioma-like components, aberrant CD34 expression, and genetic alterations involving the MAP kinase pathway. Acta Neuropathologica, 2017, 133, 417-429.	7.7	172
18	Immunohistochemical analysis of H3K27me3 demonstrates global reduction in group-A childhood posterior fossa ependymoma and is a powerful predictor of outcome. Acta Neuropathologica, 2017, 134, 705-714.	7.7	168

#	Article	IF	CITATIONS
19	Mutant IDH1 and seizures in patients with glioma. Neurology, 2017, 88, 1805-1813.	1.1	167
20	Association of Initial Viral Load in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Patients with Outcome and Symptoms. American Journal of Pathology, 2020, 190, 1881-1887.	3.8	155
21	Limited Environmental Serine and Glycine Confer Brain Metastasis Sensitivity to PHGDH Inhibition. Cancer Discovery, 2020, 10, 1352-1373.	9.4	145
22	Mutant IDH1 and thrombosis in gliomas. Acta Neuropathologica, 2016, 132, 917-930.	7.7	130
23	Loss of histone H3K27me3 identifies a subset of meningiomas with increased risk of recurrence. Acta Neuropathologica, 2018, 135, 955-963.	7.7	109
24	Primary intracranial spindle cell sarcoma with rhabdomyosarcoma-like features share a highly distinct methylation profile and DICER1 mutations. Acta Neuropathologica, 2018, 136, 327-337.	7.7	104
25	Tumor Microenvironment Is Critical for the Maintenance of Cellular States Found in Primary Glioblastomas. Cancer Discovery, 2020, 10, 964-979.	9.4	102
26	Rapid Intraoperative Diagnosis of Pediatric Brain Tumors Using Stimulated Raman Histology. Cancer Research, 2018, 78, 278-289.	0.9	98
27	Low-Grade Astrocytoma Mutations in IDH1, P53, and ATRX Cooperate to Block Differentiation of Human Neural Stem Cells via Repression of SOX2. Cell Reports, 2017, 21, 1267-1280.	6.4	95
28	The molecular landscape of ETMR at diagnosis and relapse. Nature, 2019, 576, 274-280.	27.8	94
29	Integrated Molecular-Morphologic Meningioma Classification: A Multicenter Retrospective Analysis, Retrospectively and Prospectively Validated. Journal of Clinical Oncology, 2021, 39, 3839-3852.	1.6	93
30	Polysomy for Chromosomes 1 and 19 Predicts Earlier Recurrence in Anaplastic Oligodendrogliomas with Concurrent 1p/19q Loss. Clinical Cancer Research, 2009, 15, 6430-6437.	7.0	88
31	Molecular and clinicopathologic features of gliomas harboring NTRK fusions. Acta Neuropathologica Communications, 2020, 8, 107.	5.2	84
32	DNA methylation-based classification of sinonasal undifferentiated carcinoma. Modern Pathology, 2019, 32, 1447-1459.	5.5	82
33	Dissecting the immunosuppressive tumor microenvironments in Glioblastoma-on-a-Chip for optimized PD-1 immunotherapy. ELife, 2020, 9, .	6.0	81
34	Pilocytic astrocytoma and glioneuronal tumor with histone H3 K27M mutation. Acta Neuropathologica Communications, 2016, 4, 84.	5.2	80
35	A subset of pediatric-type thalamic gliomas share a distinct DNA methylation profile, H3K27me3 loss and frequent alteration of <i>EGFR</i> . Neuro-Oncology, 2021, 23, 34-43.	1.2	75
36	Sequencing identifies multiple early introductions of SARS-CoV-2 to the New York City region. Genome Research, 2020, 30, 1781-1788.	5.5	66

#	Article	IF	CITATIONS
37	Notch signaling regulates metabolic heterogeneity in glioblastoma stem cells. Oncotarget, 2017, 8, 64932-64953.	1.8	58
38	A recurrent kinase domain mutation in PRKCA defines chordoid glioma of the third ventricle. Nature Communications, 2018, 9, 810.	12.8	56
39	Programmed death ligand 1 expression and tumor infiltrating lymphocytes in neurofibromatosis type 1 and 2 associated tumors. Journal of Neuro-Oncology, 2018, 138, 183-190.	2.9	54
40	Recurrent homozygous deletion of DROSHA and microduplication of PDE4DIP in pineoblastoma. Nature Communications, 2018, 9, 2868.	12.8	54
41	Predicting Genotype and Survival in Glioma Using Standard Clinical MR Imaging Apparent Diffusion Coefficient Images: A Pilot Study from The Cancer Genome Atlas. American Journal of Neuroradiology, 2018, 39, 1814-1820.	2.4	53
42	There is an exception to every rule—T2-FLAIR mismatch sign in gliomas. Neuroradiology, 2019, 61, 225-227.	2.2	52
43	Primary mismatch repair deficient IDH-mutant astrocytoma (PMMRDIA) is a distinct type with a poor prognosis. Acta Neuropathologica, 2021, 141, 85-100.	7.7	52
44	Cell Surface Notch Ligand DLL3 is a Therapeutic Target in Isocitrate Dehydrogenase–mutant Glioma. Clinical Cancer Research, 2019, 25, 1261-1271.	7.0	50
45	Molecular subgrouping of primary pineal parenchymal tumors reveals distinct subtypes correlated with clinical parameters and genetic alterations. Acta Neuropathologica, 2020, 139, 243-257.	7.7	50
46	Total copy number variation as a prognostic factor in adult astrocytoma subtypes. Acta Neuropathologica Communications, 2019, 7, 92.	5.2	48
47	Cardiac arrhythmia and neuroexcitability gene variants in resected brain tissue from patients with sudden unexpected death in epilepsy (SUDEP). Npj Genomic Medicine, 2018, 3, 9.	3.8	43
48	Cross-Species Genomics Reveals Oncogenic Dependencies in ZFTA/C11orf95 Fusion–Positive Supratentorial Ependymomas. Cancer Discovery, 2021, 11, 2230-2247.	9.4	39
49	Functional Precision Medicine Identifies New Therapeutic Candidates for Medulloblastoma. Cancer Research, 2020, 80, 5393-5407.	0.9	38
50	DNA Methylation–Based Classifier for Accurate Molecular Diagnosis of Bone Sarcomas. JCO Precision Oncology, 2017, 2017, 1-11.	3.0	37
51	Whole Genome DNA Methylation Analysis of Human Glioblastoma Using Illumina BeadArrays. Methods in Molecular Biology, 2018, 1741, 31-51.	0.9	36
52	Patient-Specific Screening Using High-Grade Glioma Explants to Determine Potential Radiosensitization by a TGF-l² Small Molecule Inhibitor. Neoplasia, 2016, 18, 795-805.	5.3	35
53	MiRâ€1253 exerts tumorâ€suppressive effects in medulloblastoma via inhibition of CDK6 and CD276 (B7â€H3). Brain Pathology, 2020, 30, 732-745.	4.1	35
54	Genetic and Epigenetic Features of Rapidly Progressing IDH-Mutant Astrocytomas. Journal of Neuropathology and Experimental Neurology, 2018, 77, 542-548.	1.7	34

#	Article	IF	CITATIONS
55	Recurrent fusions in PLAGL1 define a distinct subset of pediatric-type supratentorial neuroepithelial tumors. Acta Neuropathologica, 2021, 142, 827-839.	7.7	33
56	Molecular Correlates of Long Survival in IDH-Wildtype Glioblastoma Cohorts. Journal of Neuropathology and Experimental Neurology, 2020, 79, 843-854.	1.7	32
57	Analytical performance of lateral flow immunoassay for SARS-CoV-2 exposure screening on venous and capillary blood samples. Journal of Immunological Methods, 2021, 489, 112909.	1.4	32
58	Clear cell meningiomas are defined by a highly distinct DNA methylation profile and mutations in SMARCE1. Acta Neuropathologica, 2021, 141, 281-290.	7.7	31
59	Rapid progression to glioblastoma in a subset of IDH-mutated astrocytomas: a genome-wide analysis. Journal of Neuro-Oncology, 2017, 133, 183-192.	2.9	30
60	Recurrent <i>EP300-BCOR</i> Fusions in Pediatric Gliomas With Distinct Clinicopathologic Features. Journal of Neuropathology and Experimental Neurology, 2019, 78, 305-314.	1.7	29
61	Functional and topographic effects on DNA methylation in IDH1/2 mutant cancers. Scientific Reports, 2019, 9, 16830.	3.3	29
62	Prognostic Value of Tumor Microinvasion and Metalloproteinases Expression in Intracranial Pediatric Ependymomas. Journal of Neuropathology and Experimental Neurology, 2008, 67, 911-920.	1.7	26
63	Incomplete Susac syndrome exacerbated after natalizumab. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e151.	6.0	25
64	Chronic Dengue Virus Panencephalitis in a Patient with Progressive Dementia with Extrapyramidal Features. Annals of Neurology, 2019, 86, 695-703.	5.3	24
65	DNA methylation as a diagnostic tool. Acta Neuropathologica Communications, 2022, 10, 71.	5.2	24
66	Deep Learning and Pathomics Analyses Reveal Cell Nuclei as Important Features for Mutation Prediction of BRAF-Mutated Melanomas. Journal of Investigative Dermatology, 2022, 142, 1650-1658.e6.	0.7	22
67	Comparison of solid tissue sequencing and liquid biopsy accuracy in identification of clinically relevant gene mutations and rearrangements in lung adenocarcinomas. Modern Pathology, 2021, 34, 2168-2174.	5.5	21
68	Apolipoprotein L1 risk variants associate with prevalent atherosclerotic disease in African American systemic lupus erythematosus patients. PLoS ONE, 2017, 12, e0182483.	2.5	21
69	COVID-19-Induced Neurovascular Injury: a Case Series with Emphasis on Pathophysiological Mechanisms. SN Comprehensive Clinical Medicine, 2020, 2, 2109-2125.	0.6	19
70	Deformable image registration between pathological images and MR image via an optical macro image. Pathology Research and Practice, 2016, 212, 927-936.	2.3	18
71	Molecular Pathology of Gliomas. Surgical Pathology Clinics, 2021, 14, 379-386.	1.7	18
72	Long-term clinical and visual outcomes after surgical resection of pediatric pilocytic/pilomyxoid optic pathway gliomas. Journal of Neurosurgery: Pediatrics, 2019, 24, 166-173.	1.3	17

#	Article	IF	CITATIONS
73	GOPC-ROS1 Fusion Due to Microdeletion at 6q22 Is an Oncogenic Driver in a Subset of Pediatric Gliomas and Glioneuronal Tumors. Journal of Neuropathology and Experimental Neurology, 2019, 78, 1089-1099.	1.7	17
74	Anaplastic pleomorphic xanthoastrocytoma with spinal leptomeningeal spread at the time of diagnosis in an adult. Journal of Clinical Neuroscience, 2015, 22, 1370-1373.	1.5	16
75	Cortical Gray–White Matter Blurring and Cognitive Morbidity in Focal Cortical Dysplasia. Cerebral Cortex, 2015, 25, 2854-2862.	2.9	16
76	Establishing a prognostic threshold for total copy number variation within adult IDH-mutant grade II/III astrocytomas. Acta Neuropathologica Communications, 2019, 7, 121.	5.2	16
77	Genomics of MPNST (GeM) Consortium: Rationale and Study Design for Multi-Omic Characterization of NF1-Associated and Sporadic MPNSTs. Genes, 2020, 11, 387.	2.4	16
78	Functional Characterization of Brain Tumor-Initiating Cells and Establishment of GBM Preclinical Models that Incorporate Heterogeneity, Therapy, and Sex Differences. Molecular Cancer Therapeutics, 2021, 20, 2585-2597.	4.1	16
79	TSC2-mutant uterine sarcomas with JAZF1-SUZ12 fusions demonstrate hybrid features of endometrial stromal sarcoma and PEComa and are responsive to mTOR inhibition. Modern Pathology, 2022, 35, 117-127.	5.5	16
80	Genome-Wide Analysis of Glioblastoma Patients with Unexpectedly Long Survival. Journal of Neuropathology and Experimental Neurology, 2019, 78, 501-507.	1.7	15
81	Pre-treatment lymphopenia and indication of tumor-induced systemic immunosuppression in medulloblastoma. Journal of Neuro-Oncology, 2018, 136, 541-544.	2.9	14
82	YAP1-FAM118B Fusion Defines a Rare Subset of Childhood and Young Adulthood Meningiomas. American Journal of Surgical Pathology, 2021, 45, 329-340.	3.7	14
83	Osimertinib Dose Escalation Induces Regression of Progressive EGFR T790M–Mutant Leptomeningeal Lung Adenocarcinoma. Journal of Thoracic Oncology, 2017, 12, e188-e190.	1.1	13
84	Expression profiling of the adhesion G protein-coupled receptor GPR133 (ADGRD1) in glioma subtypes. Neuro-Oncology Advances, 2020, 2, vdaa053.	0.7	13
85	Genome-Wide DNA Methylation Profiles in Community Members Exposed to the World Trade Center Disaster. International Journal of Environmental Research and Public Health, 2020, 17, 5493.	2.6	13
86	Polysomy is associated with poor outcome in 1p/19q codeleted oligodendroglial tumors. Neuro-Oncology, 2019, 21, 1164-1174.	1.2	12
87	Molecular Signatures of Chromosomal Instability Correlate With Copy Number Variation Patterns and Patient Outcome in IDH-Mutant and IDH-Wildtype Astrocytomas. Journal of Neuropathology and Experimental Neurology, 2021, 80, 354-365.	1.7	12
88	Plasma cell-free circulating tumor DNA (ctDNA) detection in longitudinally followed glioblastoma patients using <i>TERT</i> promoter mutation-specific droplet digital PCR assays Journal of Clinical Oncology, 2019, 37, 2026-2026.	1.6	11
89	Comprehensive profiling of myxopapillary ependymomas identifies a distinct molecular subtype with relapsing disease. Neuro-Oncology, 2022, 24, 1689-1699.	1.2	11
90	Adult Primary Spinal Epidural Extraosseous Ewing's Sarcoma: A Case Report and Review of the Literature. Case Reports in Neurological Medicine, 2016, 2016, 1-8.	0.4	9

#	Article	IF	CITATIONS
91	Exploring DNA Methylation for Prognosis and Analyzing the Tumor Microenvironment in Pleomorphic Xanthoastrocytoma. Journal of Neuropathology and Experimental Neurology, 2020, 79, 880-890.	1.7	9
92	Feasibility and clinical utility of a pan-solid tumor targeted RNA fusion panel: A single center experience. Experimental and Molecular Pathology, 2020, 114, 104403.	2.1	9
93	LMNAâ€NTRK1 rearranged mesenchymal tumor (lipofibromatosisâ€like neural tumor) mimicking pigmented dermatofibrosarcoma protuberans. Journal of Cutaneous Pathology, 2021, 48, 290-294.	1.3	9
94	Histone H3K36I mutation in a metastatic histiocytic tumor of the skull and response to sarcoma chemotherapy. Journal of Physical Education and Sports Management, 2019, 5, a004606.	1.2	8
95	MR imaging phenotype correlates with extent of genome-wide copy number abundance in IDH mutant gliomas. Neuroradiology, 2019, 61, 1023-1031.	2.2	8
96	BCAT1 and miR-2504: novel methylome signature distinguishes spindle/desmoplastic melanoma from superficial malignant peripheral nerve sheath tumor. Modern Pathology, 2019, 32, 338-345.	5.5	8
97	Integrated Analysis of Ovarian Juvenile Granulosa Cell Tumors Reveals Distinct Epigenetic Signatures and Recurrent <i>TERT</i> Rearrangements. Clinical Cancer Research, 2022, 28, 1724-1733.	7.0	8
98	Methylation Profiling of Medulloblastoma in a Clinical Setting Permits Sub-classification and Reveals New Outcome Predictions. Frontiers in Neurology, 2020, 11, 167.	2.4	7
99	Somatic Focal Copy Number Gains of Noncoding Regions of Receptor Tyrosine Kinase Genes in Treatment-Resistant Epilepsy. Journal of Neuropathology and Experimental Neurology, 2021, 80, 160-168.	1.7	7
100	Molecular analysis of encapsulated papillary carcinoma of the breast with and without invasion. Human Pathology, 2021, 111, 67-74.	2.0	7
101	Proteomic differences in hippocampus and cortex of sudden unexplained death in childhood. Acta Neuropathologica, 2022, 143, 585-599.	7.7	7
102	Primary CNS Alveolar Rhabdomyosarcoma: Importance of Epigenetic and Transcriptomic Assays for Accurate Diagnosis. Journal of Neuropathology and Experimental Neurology, 2019, 78, 1073-1075.	1.7	6
103	Correlative study of epigenetic regulation of tumor microenvironment in spindle cell melanomas and cutaneous malignant peripheral nerve sheath tumors. Scientific Reports, 2020, 10, 12996.	3.3	6
104	Spatial progression and molecular heterogeneity of IDH-mutant glioblastoma determined by DNA methylation-based mapping. Acta Neuropathologica Communications, 2021, 9, 120.	5.2	6
105	Epigenetic and genomic profiling of chordoid meningioma: implications for clinical management. Acta Neuropathologica Communications, 2022, 10, 56.	5.2	6
106	DNA Methylation Profiling Identifies Subgroups of Lung Adenocarcinoma with Distinct Immune Cell Composition, DNA Methylation Age, and Clinical Outcome. Clinical Cancer Research, 2022, 28, 3824-3835.	7.0	6
107	Genomic Molecular Classification of CNS Malignancies. Advances in Anatomic Pathology, 2020, 27, 44-50.	4.3	5
108	Novel EWSR1â€VGLL1 fusion in a pediatric neuroepithelial neoplasm. Clinical Genetics, 2020, 97, 791-792.	2.0	5

#	Article	IF	CITATIONS
109	WNT-Activated Medulloblastomas With Hybrid Molecular Subtypes. JCO Precision Oncology, 2020, 4, 348-354.	3.0	5
110	Molecular classification of a complex structural rearrangement of the RB1 locus in an infant with sporadic, isolated, intracranial, sellar region retinoblastoma. Acta Neuropathologica Communications, 2021, 9, 61.	5.2	5
111	Diffuse midline glioma with novel, potentially targetable, <i>FGFR2–VPS35</i> fusion. Journal of Physical Education and Sports Management, 2020, 6, a005660.	1.2	5
112	A Phase I Trial of TB-403 in Relapsed Medulloblastoma, Neuroblastoma, Ewing Sarcoma, and Alveolar Rhabdomyosarcoma. Clinical Cancer Research, 2022, 28, 3950-3957.	7.0	5
113	Endothelium-Independent Primitive Myxoid Vascularization Creates Invertebrate-Like Channels to Maintain Blood Supply in Optic Gliomas. American Journal of Pathology, 2017, 187, 1867-1878.	3.8	4
114	Intraosseous Petrous Apex Schwannoma: Case Report and Review of Literature. World Neurosurgery, 2019, 132, 182-187.	1.3	4
115	Anaplastic Transformation in Myxopapillary Ependymoma: A Report of 2 Cases and Review of the Literature. Journal of Neuropathology and Experimental Neurology, 2020, 79, 1044-1053.	1.7	4
116	Suprasellar epithelioid hemangioendothelioma: Case report and review of the literature. , 2016, 7, 596.		4
117	Global DNA Methylation Profiles in Peripheral Blood of WTC-Exposed Community Members with Breast Cancer. International Journal of Environmental Research and Public Health, 2022, 19, 5104.	2.6	4
118	Registration between Pathological Image and MR Image for Comparing Different Modality Images of Brain Tumor. Analytical Cellular Pathology, 2014, 2014, 1-3.	1.4	3
119	A case of molecularly profiled extraneural medulloblastoma metastases in a child. BMC Medical Genetics, 2018, 19, 10.	2.1	3
120	ATIM-37. PHASE II, OPEN-LABEL, SINGLE ARM, MULTICENTER STUDY OF AVELUMAB WITH HYPOFRACTIONATED RADIATION (HFRT) FOR ADULT PATIENTS WITH SECONDARILY TRANSFORMED IDH-MUTANT GLIOBLASTOMA (GBM). Neuro-Oncology, 2019, 21, vi9-vi10.	1.2	3
121	Subgroup-specific outcomes of children with malignant childhood brain tumors treated with an irradiation-sparing protocol. Child's Nervous System, 2020, 36, 133-144.	1.1	3
122	NTRK2 Fusion driven pediatric glioblastoma: Identification of oncogenic Drivers via integrative Genome and transcriptome profiling. Clinical Case Reports (discontinued), 2021, 9, 1472-1477.	0.5	3
123	Connection and Deformation of Pathological Images via a Macro Image for Comparing Different Modality Images of Brain Tumor. Analytical Cellular Pathology, 2014, 2014, 1-3.	1.4	2
124	Using methylation profiling to diagnose systemic metastases of pleomorphic xanthoastrocytoma. Neuro-Oncology Advances, 2020, 2, vdz057.	0.7	2
125	Ganglioglioma in a Survivor of Infantile Glioblastoma. Journal of Pediatric Hematology/Oncology, 2020, 42, e56-e60.	0.6	2
126	ETMR-06. Molecular and clinical characteristics of CNS tumors with <i>BCOR(L1</i>) fusion/internal tandem duplication. Neuro-Oncology, 2022, 24, i50-i50.	1.2	2

#	Article	IF	CITATIONS
127	PDTM-38. PEDIATRIC MENINGIOMAS ARE CHARACTERIZED BY DISTINCT METHYLATION PROFILES DIFFERENT FROM ADULT MENINGIOMAS. Neuro-Oncology, 2018, 20, vi212-vi212.	1.2	1
128	NFM-11. PEDIATRIC MENINGIOMAS ARE MOLECULARLY DISTINCT FROM ADULT COUNTERPARTS. Neuro-Oncology, 2018, 20, i144-i145.	1.2	1
129	Molecular classification and deconvolution of the immune microenvironment in glioblastoma. Neuro-Oncology, 2021, 23, 175-176.	1.2	1
130	Abstract CT015: A phase 1 dose escalation study of TB-403 in pediatric relapsed or refractory medulloblastoma, neuroblastoma, Ewing sarcoma, or alveolar rhabdomyosarcoma. , 2021, , .		1
131	Effect of antiangiogenic therapy on tumor-associated macrophages in recurrent glioblastoma Journal of Clinical Oncology, 2012, 30, 2010-2010.	1.6	1
132	Utility of multimodality molecular profiling for pediatric patients with central nervous system tumors. Neuro-Oncology Advances, 2022, 4, vdac031.	0.7	1
133	Thoracic low grade glial neoplasm with concurrent H3 K27M and PTPN11 mutations. Acta Neuropathologica Communications, 2022, 10, 64.	5.2	1
134	Molecular Tumor Board Case Report: IDH-mutant Astrocytoma with EGFR Amplification – Genomic Profiling in Four Cases and Review of Literature. Neuro-Oncology Advances, 0, , .	0.7	1
135	MEDB-14. Clinical outcome of pediatric medulloblastoma patients with Li-Fraumeni syndrome. Neuro-Oncology, 2022, 24, i107-i107.	1.2	1
136	RARE-15. Astroblastoma, <i>MN1</i> altered comprises two molecularly and clinically distinct subgroups defined by the fusion partners <i>BEND2</i> and <i>CXXC5</i> . Neuro-Oncology, 2022, 24, i12-i13.	1.2	1
137	GENO-20NOVEL CANDIDATE ONCOGENIC DRIVERS IN PINEOBLASTOMA. Neuro-Oncology, 2015, 17, v95.4-v96.	1.2	0
138	IMST-40. REPROGRAMMING OF THE TUMOR IMMUNE MICROENVIRONMENT BY AN ANG-2/VEGF BISPECIFIC ANTIBODY DELAYS TUMOR GROWTH AND PROLONGS SURVIVAL IN PRECLINICAL GBM MODELS. Neuro-Oncology, 2016, 18, vi95-vi95.	1.2	0
139	HG-127ANAPLASTIC PLEOMORPHIC XANTHOASTROCYTOMAS: A CLINICOPATHOLOGIC AND MOLECULAR PROFILE. Neuro-Oncology, 2016, 18, iii77.3-iii77.	1.2	0
140	HG-73SAFETY AND FEASIBILITY OF A MULTI-INSTITUTIONAL PHASE II TRIAL INCOPORATING BIOPSY AND MOLECULARLY DETERMINED TREATMENT OF CHILDREN AND YOUNG ADULTS WITH NEWLY DIAGNOSED DIFFUSE INTRINSIC PONTINE GLIOMAS (DIPG). Neuro-Oncology, 2016, 18, iii65.1-iii65.	1.2	0
141	LG-67MIDBRAIN GLIOMAS: A LARGE SERIES OF CLINICALLY AND RADIOGRAPHICALLY HETEROGENEOUS TUMORS. Neuro-Oncology, 2016, 18, iii94.2-iii94.	1.2	0
142	LG-74STRATEGIES FOR THE SURGICAL MANAGEMENT OF PEDIATRIC OPTIC PATHWAY GLIOMAS - EXPERIENCE WITH 100 PATIENTS. Neuro-Oncology, 2016, 18, iii95.5-iii96.	1.2	0
143	TB-27SUBGROUP-SPECIFIC OUTCOMES OF CHILDREN WITH MALIGNANT CHILDHOOD BRAIN TUMORS TREATED WITH AN IRRADIATION-SPARING PROTOCOL. Neuro-Oncology, 2016, 18, iii173.3-iii173.	1.2	0
144	MPTH-34. THE PROGNOSTIC VALUE OF POLYSOMY IN OLIGODENDROGLIAL TUMORS. Neuro-Oncology, 2016, 18, vi113-vi113.	1.2	0

#	Article	IF	CITATIONS
145	MPTH-59. ANAPLASTIC PLEOMORPHIC XANTHOASTROCYTOMAS: AÂCLINICOPATHOLOGIC AND MOLECULAR PROFILE. Neuro-Oncology, 2016, 18, vi118-vi118.	1.2	0
146	NIMG-76. MIDBRAIN GLIOMAS: AÂLARGE SERIES THAT IDENTIFIES FEATURES CORRESPONDING WITH OUTCOME. Neuro-Oncology, 2016, 18, vi141-vi141.	1.2	0
147	STMC-21. ASTROCYTOMA MUTATIONS IDH1, p53 AND ATRX COOPERATE TO BLOCK DIFFERENTIATION OF NEURAL STEM CELLS VIA Sox2. Neuro-Oncology, 2016, 18, vi187-vi187.	1.2	0
148	STMC-25. GPR133 PROMOTES HYPOXIA-DRIVEN TUMOR PROGRESSION IN GLIOBLASTOMA. Neuro-Oncology, 2016, 18, vi187-vi188.	1.2	0
149	GENE-02. PERIPHERAL BLOOD DNA METHYLATION PROFILES IDENTIFY IDH1/2 MUTATION STATUS IN ADULTS WITH DIFFUSE GLIOMA. Neuro-Oncology, 2017, 19, vi92-vi92.	1.2	0
150	GENE-14. DNA METHYLATION AND PROTEOMIC ALTERATIONS IDENTIFY HISTOLOGICALLY-DEFINED TUMOR CELL POPULATIONS AND CHARACTERIZE INTRATUMOR HETEROGENEITY IN GLIOBLASTOMA. Neuro-Oncology, 2018, 20, vi105-vi105.	1.2	0
151	TBIO-16. AUTOMATED CELL ENRICHMENT AND DIGITAL CELL SORTING USING DIELECTROPHORETIC ARRAYS FOR ISOLATION OF CIRCULATING TUMOR CELLS IN PEDIATRIC BRAIN TUMOR PATIENTS. Neuro-Oncology, 2018, 20, i183-i183.	1.2	0
152	GENE-16. CLINICALLY AGGRESSIVE MENINGIOMAS ARE CHARACTERIZED BY MUTATIONAL SIGNATURES ASSOCIATED WITH DEFECTIVE DNA REPAIR AND MUTATIONS IN CHROMATIN REMODELING GENES. Neuro-Oncology, 2018, 20, vi106-vi106.	1.2	0
153	MNGI-14. LOSS OF HISTONE H3K27me3 IDENTIFIES A SUBSET OF MENINGIOMAS WITH INCREASED RISK OF RECURRENCE. Neuro-Oncology, 2018, 20, vi151-vi151.	1.2	0
154	High-Grade Glioma, Including Diffuse Intrinsic Pontine Glioma. , 2018, , 193-221.		0
155	Revisiting multifocal breast cancer: a clonality study of ductal carcinoma using whole exome sequencing. Human Pathology, 2019, 94, 71-77.	2.0	0
156	Whole transcriptome analysis identifies upregulated genes and pathways in ductal carcinoma in situ mimicking usual ductal hyperplasia. Human Pathology: Case Reports, 2019, 17, 200308.	0.2	0
157	GENE-06. DISTINCT MOLECULAR SUBGROUPS OF TUMORS OF THE PINEAL REGION CORRELATE WITH CLINICAL PARAMETERS AND GENETIC ALTERATIONS. Neuro-Oncology, 2019, 21, ii81-ii82.	1.2	0
158	PATH-40. PROFILING PLEOMORPHIC XANTHROASTROCYTOMA WITH DNA METHYLATION AND EXPLORING THE TUMOR IMMUNE CELL-TYPE COMPOSITION WITH METHYLATION-BASED DECONVOLUTION. Neuro-Oncology, 2019, 21, vi152-vi152.	1.2	0
159	GENE-62. IDENTIFICATION OF FGFR4 p.G388R VARIANT IN CEREBELLAR HEMANGIOBLASTOMAS. Neuro-Oncology, 2019, 21, vi111-vi111.	1.2	0
160	NIMG-09. NONINVASIVE PERFUSION IMAGING BIOMARKER OF MALIGNANT GENOTYPE IN ISOCITRATE DEHYDROGENASE MUTANT GLIOMAS. Neuro-Oncology, 2019, 21, vi163-vi163.	1.2	0
161	Genome-wide association study to reveal novel germline markers of melanoma survival Journal of Clinical Oncology, 2021, 39, 9581-9581.	1.6	0
162	Prognostic value of tumor microinvasion and metalloproteinases expression in intracranial pediatric ependymomas. FASEB Journal, 2008, 22, 706.8.	0.5	0

#	Article	IF	CITATIONS
163	Abstract LB-339: Increase in tumor-associated macrophages (TAMs) after antiangiogenic therapy is associated with poor survival in recurrent glioblastoma (GBM) patients , 2013, , .		0
164	Development of a viewing system for a whole tissue from multiple tissue blocks. FASEB Journal, 2013, 27, 52.4.	0.5	0
165	Neuropilin-1 (Nrp-1) as a prognostic biomarker and potential drug target for pediatric medulloblastoma Journal of Clinical Oncology, 2013, 31, 2056-2056.	1.6	0
166	Abstract LB-172: Novel candidate oncogenic drivers in pineoblastoma. , 2015, , .		0
167	A DNA methylation-based classifier for accurate molecular diagnosis of bone sarcomas Journal of Clinical Oncology, 2017, 35, 11034-11034.	1.6	0
168	DNA methylation-based classifier for diagnosis of endometrial cancer Journal of Clinical Oncology, 2018, 36, e17570-e17570.	1.6	0
169	Genomic Applications in Brain Tumors. , 2019, , 289-308.		Ο
170	Single cell analysis of urothelial carcinoma (UC) liver metastases identifies epithelial-mesenchymal transition (EMT) as a potential mechanism of resistance to immunotherapy Journal of Clinical Oncology, 2019, 37, e16018-e16018.	1.6	0
171	MBCL-01. METHYLATION PROFILING OF PEDIATRIC MEDULLOBLASTOMA IN SAUDI ARABIA IN A CLINICAL SETTING PERMITS SUB-CLASSIFICATION AND REVEALS NEW OUTCOME PREDICTIONS. Neuro-Oncology, 2020, 22, iii386-iii387.	1.2	0
172	EPEN-18. CROSS-SPECIES GENOMICS IDENTIFIES GLI2 AS AN ONCOGENE OF C11orf95 FUSION-POSITIVE SUPRATENTORIAL EPENDYMOMA. Neuro-Oncology, 2020, 22, iii311-iii311.	1.2	0
173	Molecular neuropathology: The times they are a-changin'. Neuro-Oncology, 2022, , .	1.2	Ο
174	EPEN-18. Oncogenic 3D genome conformations identify novel therapeutic targets in ependymoma. Neuro-Oncology, 2022, 24, i42-i42.	1.2	0
175	MEDB-83. A novel epigenetic nanotherapeutic strategy to induce medulloblastoma differentiation. Neuro-Oncology, 2022, 24, i126-i126.	1.2	Ο
176	HGG-60. Structural variants shape driver combinations and outcomes in pediatric high-grade glioma. Neuro-Oncology, 2022, 24, i75-i76.	1.2	0
177	EPEN-27. Epigenetic dissection of spinal ependymomas (SP-EPN) separates tumors with and without <i>NF2</i> mutation. Neuro-Oncology, 2022, 24, i44-i45.	1.2	О